Astrana Health director granted 4,525 restricted shares

Dai, Weili reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Dai, Weili reported acquisition or exercise transactions in this Form 4 filing.

Astrana Health director Weili Dai received a grant of 4,525 shares of restricted common stock under the company’s 2024 Equity Incentive Plan. These shares vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual stockholders meeting, bringing Dai’s direct holdings to 18,188 shares.

Insider Trade Summary

Grant/Award: 4,525 shares

Grant/Award 1 txn

Insider Dai, Weili

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	4,525	$0.00	$0.00

Holdings After Transaction: Common Stock — 18,188 shares (Direct)

Footnotes (2)

1. F1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.
2. F2. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

Key Figures

Restricted stock grant: 4,525 shares Price per share for grant: $0.00 per share Total shares after transaction: 18,188 shares +1 more

4 metrics

Restricted stock grant 4,525 shares Common stock award to director Weili Dai

Price per share for grant $0.00 per share Equity compensation, not open-market purchase

Total shares after transaction 18,188 shares Dai’s direct holdings following the award

Vesting date trigger June 10, 2027 Earlier of this date or 2027 annual meeting

Key Terms

restricted stock, 2024 Equity Incentive Plan, vest

3 terms

restricted stock financial

"Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027..."

Shares granted to an individual that carry limits on transfer or sale until certain conditions are met, such as staying with the company for a set time or hitting performance targets. Think of them as a locked gift that gradually opens; for investors they matter because they affect how many shares may enter the market later, signal management incentives and potential dilution, and reveal confidence in future company performance.

2024 Equity Incentive Plan financial

"Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan..."

vest financial

"which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting..."

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Astrana Health (ASTH) director Weili Dai report on this Form 4?

Director Weili Dai reported receiving a grant of 4,525 shares of restricted Astrana Health common stock. The award was issued at no cash cost as part of equity compensation and increases Dai’s direct holdings to 18,188 shares after the transaction.

How many Astrana Health (ASTH) shares did Weili Dai acquire in this transaction?

Weili Dai acquired 4,525 shares of restricted Astrana Health common stock. These shares are part of an equity award, not an open-market purchase, and were granted with a reported price per share of $0.00 as compensation.

When do Weili Dai’s new restricted Astrana Health (ASTH) shares vest?

The 4,525 restricted shares vest on the earlier of June 10, 2027 or the date of Astrana Health’s 2027 annual meeting of stockholders. Vesting means the shares become fully owned and no longer subject to forfeiture conditions.

What is Weili Dai’s total Astrana Health (ASTH) share ownership after the grant?

After receiving the 4,525-share restricted stock grant, Weili Dai directly holds 18,188 shares of Astrana Health common stock. This total includes the newly granted restricted shares, which remain subject to vesting conditions until the earlier of June 10, 2027 or the 2027 annual meeting.

Under which plan was Weili Dai’s Astrana Health (ASTH) equity award granted?

The 4,525 restricted shares were granted under Astrana Health’s 2024 Equity Incentive Plan. This plan provides stock-based compensation to directors and other eligible participants, aligning part of their compensation with the company’s common stock performance over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/12/2026 - 04:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Dai, Weili

(Last) (First) (Middle)

C/O ASTRANA HEALTH, INC.

1668 S. GARFIELD AVE, 2ND FLOOR

(Street)

ALHAMBRA CALIFORNIA 91801

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Astrana Health, Inc. [ ASTH ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	06/10/2026		A		4,525(1)	A	$0	18,188(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Restricted shares of the Issuer's common stock granted pursuant to the Issuer's 2024 Equity Incentive Plan, which will vest on the earlier of (i) June 10, 2027 or (ii) the date of the Issuer's 2027 annual meeting of stockholders.

2. Includes 4,525 shares of restricted stock, which will vest on the earlier of June 10, 2027 or the date of the Issuer's 2027 annual meeting of stockholders.

	/s/ Kathy Diep, as Attorney-in-Fact	06/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)